Oura buys Counsel Health for $625 million: the ring wants to be the gateway to your doctor, with AI in between

By Bloomberg (via The Seattle Times) · November 10, 2026.

Oura has agreed to buy Counsel Health, a startup that offers AI and on-demand doctors, for $625 million. According to Bloomberg, it is the company's largest acquisition "by multiples," in the words of its CEO, Tom Hale.

The deal comes on the back of strong numbers, according to Oura itself: revenue of $533 million in its fiscal fourth quarter (ended September 30), up 153% year over year. In fiscal 2026 it brought in about $1.75 billion, up 92%. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $87 million, a 16% margin.

The financial context matters. Oura was set to go public in late September and shelved the plan at the last minute, citing "market uncertainty." Hale said he has no updates on the timing of the IPO. He did stress that generating cash allows the company to move into new businesses.

Counsel Health had already been integrated into the Oura app since June. Here is how it works: users ask questions about their health and receive AI-generated answers that draw on data from the ring and other medical information. If a formal diagnosis is needed, they can speak with a human doctor.

Counsel's team, about 70 people, is joining Oura. Its CEO, Muthu Alagappan, will become head of clinical AI. The network of on-demand doctors numbers around 50, and Alagappan says it will grow. Counsel also sells to health insurers, a business Oura wants to keep. That would give it access to patients beyond its more than 6 million members.

**Our take.** This is not a technology purchase but a positioning play. Oura wants to move from measuring (sleep, heart rate, temperature) to being the first point of contact when that data raises concerns. Whoever sits between the user and the doctor captures the relationship, and with it the data and the recurring revenue.

The hybrid design, with AI that guides and a human who diagnoses, is sensible. It is the prudent formula for healthcare: AI absorbs the volume of simple queries while the doctor retains responsibility. Broadly speaking, that division of roles is what is most likely to take hold in the near term.

There are risks worth not glossing over. A wearable generates a lot of data, and not all of it is clinically relevant: the danger of false alarms and metrics-driven anxiety is real. There is also a privacy question. Continuous biometric data, tied to an insurer, is a highly sensitive asset, and the company has not detailed here how it will keep the two separate. And paying $625 million for a 70-employee business is a bet, not a proof.

Even so, the underlying direction is good. Continuous, preventive health care that detects deviations before symptoms appear is one of the concrete paths toward a medicine that eradicates or contains diseases before they develop. That kind of healthcare abundance depends on access to medical judgment ceasing to be a scarce privilege. Having a consumer company lead the way, however, demands regulation and transparency about what the AI does and what the doctor does.

What to watch in the coming months: how many users actually use the medical pathway, what happens with the IPO, and what guarantees Oura offers on the use of data with insurers.